The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

NanoVation will receive $600m in upfront cash and potential milestone payments, as well as tiered royalties on future product ...

2024年3月15日，尽管Novo Nordisk（NYSE:NVO）的II期肥胖试验结果不尽如人意，TD Cowen仍维持其买入评级和155.00美元的目标价。该试验研究了公司的CB1阻断剂monlunabant，在16周时显示约6-7%的体重减轻。 这次更新未能达到预期的疗效和安全性，但未发现严重的神经精神不良事件。然而，接受monlunabant治疗的参与者出现轻度至中度神经精神副作用的情况 ...

诺和诺德公司股价今日出现显著下跌，在其肥胖药物monlunabant试验结果不如预期后暴跌超过4%。这一跌幅使得公司股价降至8月10日以来的最低点。

Key Takeaways Novo Nordisk's U.S.-listed shares lost ground Friday after a Phase 2a trial of the pharmaceutical firm’s latest ...

By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN (Reuters) -Novo Nordisk's shares fell nearly 5% on Friday after ...

In this morning’s readout from Novo's phase 2 trial of monlunabant in 243 people with obesity and metabolic syndrome, it ...

A next-generation obesity drug candidate from Novo Nordisk produced modest weight loss, along with a higher rate of some ...

Novo Nordisk announced Phase 2a trial results for monlunabant. The trial demonstrated a weight reduction of 7.1 kg with a 10 ...

Shares were down 4.3% at 1330 GMT, the lowest since August 8, after the company announced headline results from its trial of ...

Novo Nordisk announced positive Phase 2a trial results for monlunabant, showing significant weight loss with a 10 mg dose.

Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral ...